Amendments to the Specification:

Please add the following new paragraph at page 1, line 7, before "Field of the Invention":

--Government Rights

This invention was made with support from the U.S. government under grant number NIH CA40035 awarded by the National Institutes of Health. The government has certain rights in the invention.--

Please replace the paragraph beginning at page 23, line 11, as with the following amended paragraph:

Other preferred humanized anti-VLA4 antibody homologs are described by Athena Neurosciences, Inc. in PCT/TJS95/01219 (27 July 1995) and corresponding U.S. Patent No. 5,840,299. These humanized anti- VLA-4 antibodies comprise a humanized light chain and a humanized heavy chain. The humanized light chain comprises three complementarity determining regions (CDRI, CDR2 and CDR3) having amino acid sequences from the corresponding complementarity determining regions of a mouse [[21- 6]] 21.6 immunoglobulin light chain, and a variable region framework from a human kappa light chain variable region framework sequence except in at least position the amino acid position is occupied by the same amino acid present in the equivalent position of the mouse 21.6 immunoglobulin light chain variable region framework. The humanized heavy chain comprises three complementarity determining regions (CDR 1, CDR2 and CDR3) having amino acid sequences from the corresponding complementarity determining regions of a mouse [[21- 6]] 21.6 immunoglobulin heavy chain, and a variable region framework from a human heavy chain variable region framework sequence except in at least one position the amino acid position is occupied by the same amino acid present in the equivalent position of the mouse [[21- 6]] 21.6 immunoglobulin heavy chain variable region framework.